- Home
- BIIB vs ARES Comparison
BIIB vs ARES Comparison
Compare BIIB & ARES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- ARES
- Stock Information
- Founded
- BIIB 1978
- ARES 1997
- Country
- BIIB United States
- ARES United States
- Employees
- BIIB N/A
- ARES N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- ARES Investment Managers
- Sector
- BIIB Health Care
- ARES Finance
- Exchange
- BIIB Nasdaq
- ARES Nasdaq
- Market Cap
- BIIB 18.8B
- ARES 37.1B
- IPO Year
- BIIB 1991
- ARES 2014
- Fundamental
- Price
- BIIB $130.13
- ARES $174.81
- Analyst Decision
- BIIB Buy
- ARES Strong Buy
- Analyst Count
- BIIB 27
- ARES 14
- Target Price
- BIIB $188.17
- ARES $172.93
- AVG Volume (30 Days)
- BIIB 1.2M
- ARES 1.5M
- Earning Date
- BIIB 07-31-2025
- ARES 08-01-2025
- Dividend Yield
- BIIB N/A
- ARES 2.56%
- EPS Growth
- BIIB 26.39
- ARES N/A
- EPS
- BIIB 10.12
- ARES 1.76
- Revenue
- BIIB $9,816,400,000.00
- ARES $4,266,223,000.00
- Revenue This Year
- BIIB N/A
- ARES $16.09
- Revenue Next Year
- BIIB N/A
- ARES $23.61
- P/E Ratio
- BIIB $12.85
- ARES $99.47
- Revenue Growth
- BIIB 1.59
- ARES 21.00
- 52 Week Low
- BIIB $110.04
- ARES $110.63
- 52 Week High
- BIIB $238.00
- ARES $200.49
- Technical
- Relative Strength Index (RSI)
- BIIB 52.92
- ARES 59.79
- Support Level
- BIIB $123.90
- ARES $171.12
- Resistance Level
- BIIB $134.75
- ARES $179.94
- Average True Range (ATR)
- BIIB 3.63
- ARES 3.91
- MACD
- BIIB 0.25
- ARES 0.55
- Stochastic Oscillator
- BIIB 59.97
- ARES 73.17
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About ARES Ares Management Corporation
Ares Management Corp is an asset management company. It offers investors investment-related advice and strategies for capital growth. The company's operating segments include Credit Group, Private Equity Group, Real Assets, Secondaries Group, and Others. Its Credit Group generates maximum revenue and manages credit strategies across the liquid and illiquid spectrum. Private Equity Group manages investment strategies categorized as corporate private equity, infrastructure and power, and special opportunities, Real Estate Group manages comprehensive equity and debt strategies across real estate & infrastructure investments. The Secondaries Group invests in secondary markets across a range of alternative asset class strategies, including private equity, real estate, infrastructure, & credit.